Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 21, 2024Scientific ReportsOpen Access

The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

ZDZongren DingFujian Medical UniversityGFGuoxu FangShanghai UniversityYTYanyan TangGuangxi Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ding et al. (2024) studied this question.

synapsesocial.com/papers/68e63c18b6db6435875ce2abhttps://doi.org/10.1038/s41598-024-63571-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review2020 · 122 citations
  2. 2Correlation and efficacy of TACE combined with lenvatinib plus PD ‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features2023 · 45 citations
  3. 3Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)2022 · 466 citations
  4. 4Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study2023 · 11 citations
  5. 5Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study2023 · 88 citations